As for the XRCC1 Arg194Trp polymorphism, sequential cumulative meta-analyses consistently and stably showed equivalent effects of better response rates to platinum-based chemotherapy treatment with advanced lung cancer patients since the several initial studies were pooled, which also showed the stable time-dependent trend (Fig. 4). The gene discussed is XRCC1; the disease is lung carcinoma.